Trends of denosumab-related publications in web of science.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
27 Jan 2023
27 Jan 2023
Historique:
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
31
1
2023
Statut:
ppublish
Résumé
Denosumab is a human monoclonal antibody that targets nuclear factor-kappa B ligand and is highly effective in blocking bone resorption. Bibliometrics can intuitively show the research development process, research status, research hotspots and development trend of a certain topic for researchers. This study assessed the course of research and development for denosumab in terms of publications over the past 2 decades. Web of Science databases were searched to identify publications related to research on denosumab from January 1, 2005 to December 31, 2022. The VOS Viewer software (version 1.6.17) and Bibliometrix package in R (version 4.1.3) were used in this study. There were 5119 denosumab-related publications during this period. The total number of citations of denosumab-related publications reached 94917. The most articles were published in the field of Endocrinology Metabolism. As an international language, English remains the most popular language for writing papers. Five of the top ten institutions originated in the USA. Through the VOS Viewer analysis, we found that the relationships between Amgen Inc. with its collaborations were grouped into 4 clusters, the USA was the mainland for research and development on denosumab, closely collaborating with many other countries, such as Canada, Japan, England, and China. Wagman RB from USA was the most prolific author with 119 publications. The journal with the most publications was Osteoporosis International (481 publications). The most cited article was "Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis" with 2053 citations. The clinical trial comprised 6 of the 10 most frequently cited publications, and the rest consisted of reviews. The most frequent keywords for publications since January 1, 2014 were "prevention" and "management," indicating that a number of prevention and management measures have been developed to regulate the use of denosumab in treating osteoporosis. Our research provided a comprehensive review of denosumab-related publications, suggesting that the development of denosumab is a long process and numerous clinical trials have been conducted before applications in clinical settings.
Identifiants
pubmed: 36705356
doi: 10.1097/MD.0000000000032784
pii: 00005792-202301270-00012
pmc: PMC9876013
doi:
Substances chimiques
Denosumab
4EQZ6YO2HI
Antibodies, Monoclonal
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e32784Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Tuck SP, Francis RM. Osteoporosis. Postgrad Med J. 2002;78:526.
Caroli A, Poli A, Ricotta D, et al. Invited review: dairy intake and bone health: a viewpoint from the state of the art. J Dairy Sci. 2011;94:5249–62.
Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci U S A. 1990;87:7260–64.
Deeks ED. Denosumab: a review in postmenopausal osteoporosis. Drugs Aging. 2018;35:163–73.
Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–70.
Ozsoy Z, Demir E. Correction to: which bariatric procedure is the most popular in the world? A bibliometric comparison. Obes Surg. 2018;28:2353–2353.
van Eck NJ, Waltman L. Software survey: VOS viewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38.
Aria M, Alterisio A, Scandurra A, et al. The scholar best friend: research trends in dog cognitive and behavioral studies. Anim Cogn. 2021;24:541–53.
Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.
Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377:1276–87.
Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.
Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97–104.
Brown JE, Coleman RE. Denosumab in patients with cancer–a surgical strike against the osteoclast. Nat Rev Clin Oncol. 2012;9:110–8.
Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab versus bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179:R31–45.
Pan KS, Boyce AM. Denosumab treatment for giant cell tumors, aneurysmal bone cysts, and fibrous dysplasia–Risks and benefits. Curr Osteoporos Rep. 2021;19:141–50.
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;26:756.
Gambacciani M, Levancini M. Management of postmenopausal osteoporosis and the prevention of fractures. Panminerva Med. 2014;56:115–31.